Among patients with actively treated RA, eGFRcys is consistently lower than eGFRcr. Neither eGFRcys nor eGFRcr demonstrated a change following RA treatments, despite reductions in the disease activity biomarker TNF-RI. Further studies incorporating directly measured GFR are warranted.

P=N/A, N=1000, Recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

He responded poorly to cytotoxic drugs, but achieved a durable complete remission with three cycles of oral prednisolone...However, he achieved complete remission with a combination of oral methotrexate and vincristine...There is no universal standard guideline for managing Rosai-Dorfman disease. However, patients with symptomatic disease, those experiencing emergency symptoms, and cases of relapse will require medical or surgical intervention to improve their outcomes.

A 25-year-old woman with pre-existing Hashimoto's thyroiditis developed progressive bilateral nodular scleritis with anterior uveitis that proved completely refractory to high-dose corticosteroids, methotrexate, and conventional disease-modifying antirheumatic drugs, along with papilledema and granulomatous rosacea, suggesting systemic inflammation. Recognition of this molecular target enabled precision therapy with fostamatinib, a spleen tyrosine kinase (Syk) inhibitor, combined with adalimumab, a tumor necrosis factor-alpha (TNF-α) inhibitor, resulting in complete and sustained remission of all inflammatory manifestations over 18 months of follow-up. This case underscores the critical importance of maintaining high clinical suspicion for paraneoplastic autoimmune syndromes in patients with treatment-refractory inflammatory conditions, particularly when accompanied by atypical systemic or unexplained laboratory findings, and demonstrates that molecularly targeted precision medicine approaches can transform treatment outcomes in complex paraneoplastic rheumatic disorders.

Importantly, our AI-aided approach not only identified this axis but also predicted its vulnerability to metabolic intervention: both methotrexate treatment and LDHA knockdown restored metabolic balance, reversed T‑cell exhaustion, and suppressed tumor growth. These findings highlight the power of ML in uncovering multi-targetable metabolic-immune networks and in guiding therapeutic strategies to overcome immune evasion in DLBCL.

The primary endpoint of the SELECT-SWITCH trial was met, with a higher percentage of patients with active RA who switched to upadacitinib after first TNFi failure achieving DAS28-CRP ≤3.2 at 12 weeks than those cycling to a second TNFi, adalimumab, with generally similar safety profiles.

In contrast, chemotherapy-induced seizures, particularly those associated with high-dose methotrexate, arise from disrupted folate metabolism, intracellular oxidative stress, and subsequent N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity. We provide a comparative analysis of these pathways, integrating current evidence on pharmacogenomic susceptibility-including polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and drug transporter genes-as well as epigenetic factors. By synthesizing these molecular insights, we propose a mechanistic framework for precise clinical differentiation, which may inform biomarker-driven diagnostic approaches and targeted neuroprotective strategies in this vulnerable population.

The study highlights the importance of these MMPs polymorphisms as potential markers for predicting susceptibility to oral mucositis, suggesting that these data could help tailor treatments to minimise the occurrence and severity of mucositis.

In this study, we comprehensively evaluated DAMA tumors naïve and exposed to methotrexate, assessing their histopathological, molecular, and genomic features. Our findings reveal that the DAMA model presents a platform to model the human triple-negative breast cancer (TNBC), as it exhibits substantial macrophage infiltration, the tumors display dysregulation of oncogenes Bcl2, Egfr, and potentially Myc, suggesting apoptotic resistance as a key mechanism driving growth. These characteristics position the DAMA model as a potential preclinical model for investigating TNBC biology, therapeutic responses, and drug toxicity.

Lastly, the alteration in nuclear morphology in all three cancer cells post treatment with MTX-MWCNTs was evaluated through 4',6-diamidino-2-phenylindole (DAPI) staining followed by fluorescence microscopy. Collectively, the obtained findings highlight that MTX-MWCNT efficiently induces apoptosis and inhibits angiogenesis while maintaining significant biosafety, establishing it as an emerging nanoscale platform for targeted cancer therapy.

The patient received high-dose methotrexate-based chemotherapy according to the DeAngelis protocol, combined with rituximab, selected to optimise disease control while minimising the neurotoxicity associated with whole-brain radiotherapy. She achieved visual recovery to 6/9 and regression of the central nervous system (CNS) lesion. This case underscores the importance of recognising pathognomonic retinal signs and employing molecular immunophenotyping to enable timely, life-saving, neuro-sparing therapy.

lncRNAs function as context-dependent modulators of MTX PK/PD processes rather than primary drug targets. Current evidence is heterogeneous, future studies integrating functional genomics, PK measurements, and prospective clinical validation are required to establish lncRNAs as predictive biomarkers or therapeutic targets in MTX precision pharmacology.